Tempus AI (TEM) Expected to Announce Earnings on Tuesday

Tempus AI (NASDAQ:TEM) is anticipated to issue its Q1 2025 quarterly earnings data after the market closes on Tuesday, May 6th. Analysts expect Tempus AI to post earnings of ($0.27) per share and revenue of $248.13 million for the quarter.

Tempus AI Trading Up 10.0 %

Shares of NASDAQ TEM opened at $57.06 on Friday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI has a twelve month low of $22.89 and a twelve month high of $91.45. The firm has a fifty day simple moving average of $48.11 and a 200 day simple moving average of $50.64.

Insider Activity at Tempus AI

In other Tempus AI news, Director Wayne A.I. Frederick sold 3,000 shares of the company’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $45.54, for a total value of $136,620.00. Following the completion of the sale, the director now directly owns 26,514 shares of the company’s stock, valued at approximately $1,207,447.56. This represents a 10.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Andrew Polovin sold 13,135 shares of Tempus AI stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $45.98, for a total transaction of $603,947.30. Following the transaction, the executive vice president now directly owns 154,171 shares in the company, valued at approximately $7,088,782.58. This represents a 7.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,409,308 shares of company stock valued at $263,006,605 over the last 90 days. Insiders own 27.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TEM shares. Loop Capital cut their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Bank of America raised their price objective on shares of Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. BTIG Research began coverage on shares of Tempus AI in a research report on Monday, April 21st. They set a “buy” rating and a $60.00 target price on the stock. Guggenheim restated a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. Finally, Morgan Stanley upped their price objective on shares of Tempus AI from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, March 6th. Six investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $61.08.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.